Long-Term Liabilities: The sum of all non-current liabilities.
Acumen Pharmaceuticals, Inc. (ABOS) had Long-Term Liabilities of $29.64M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-28.80M |
|
-- |
|
-- |
|
$30.37M |
|
$-30.37M |
|
$1.57M |
|
$-28.80M |
|
$-28.80M |
|
$-28.80M |
|
$-28.80M |
|
$-28.80M |
|
$-28.80M |
|
$-30.37M |
|
$-30.91M |
|
60.53M |
|
60.53M |
|
$-0.48 |
|
$-0.48 |
|
| Balance Sheet Financials | |
$154.95M |
|
-- |
|
$49.53M |
|
$204.48M |
|
$19.32M |
|
$29.53M |
|
|
Long-Term Liabilities |
$29.64M |
$48.96M |
|
$155.52M |
|
$155.52M |
|
$155.52M |
|
60.57M |
|
| Cash Flow Statement Financials | |
$-34.12M |
|
$28.69M |
|
$-0.04M |
|
$35.86M |
|
$30.39M |
|
$-5.47M |
|
$2.47M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.02 |
|
-- |
|
-- |
|
0.16 |
|
0.19 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-34.20M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-18.52% |
|
-18.52% |
|
-14.08% |
|
-15.56% |
|
$2.57 |
|
$-0.56 |
|
$-0.56 |
|